- Home
- VITL vs RGNX Comparison
VITL vs RGNX Comparison
Compare VITL & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VITL | RGNX |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.5M | 528.6M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | VITL | RGNX |
|---|---|---|
| Price | $12.71 | $13.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $32.00 | $28.75 |
| AVG Volume (30 Days) | ★ 2.5M | 2.4M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.03 | 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $759,444,000.00 | $10,393,000.00 |
| Revenue This Year | $19.72 | $51.21 |
| Revenue Next Year | $17.02 | $19.08 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 25.26 | ★ 126.48 |
| 52 Week Low | $7.95 | $5.46 |
| 52 Week High | $53.13 | $16.19 |
Technical Indicators
Market Signals| Indicator | VITL | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 68.89 | 83.90 |
| Support Level | $12.09 | $12.87 |
| Resistance Level | $13.47 | $13.86 |
| Average True Range (ATR) | 0.66 | 1.02 |
| MACD | 0.25 | 0.63 |
| Stochastic Oscillator | 89.84 | 90.67 |
Price Performance
Historical ComparisonAbout VITL Vital Farms Inc.
Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).
About RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.